Novel molecule and diagnosis method

A substantially isolated dimer comprising first and second cross-linked polypeptides, wherein said polypeptides comprise the extracellular domain portions of the HLA-B27 heavy chain and are capable of binding a HLA-B27 epitope, or a substantially isolated functional dimeric or multimeric analogue th...

Full description

Saved in:
Bibliographic Details
Main Authors ANDREW JAMES MCMICHAEL, PAUL BOWNESS, RACHEL LOUISE ALLEN
Format Patent
LanguageEnglish
Published 03.04.2003
Edition7
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:A substantially isolated dimer comprising first and second cross-linked polypeptides, wherein said polypeptides comprise the extracellular domain portions of the HLA-B27 heavy chain and are capable of binding a HLA-B27 epitope, or a substantially isolated functional dimeric or multimeric analogue thereof which is capable of binding said HLA-B27 epitope and/or competes for binding to a specific receptor for said dimer. The dimer can be used to determine the onset of, or predisposition to a spondyloarthropathy. The dimer can also be used as a treatment or prophylactic for a spondyloarthropathy.
Bibliography:Application Number: AU19990038390